Brainstorm Cell Therapeutics Q2 2025 Earnings Report

Brainstorm Cell Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.41
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Brainstorm Cell Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Brainstorm Cell Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/14/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, August 14, 2025
• Conference Call Time: 8:30AM ET

Brainstorm Cell Therapeutics (NASDAQ:BCLI), a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Brainstorm Cell Therapeutics Q2 2025 Earnings Call Transcript

Key Takeaways

• Negative Sentiment: The company emphasized that its forward-looking statements about future operations, clinical results, and market potential are subject to significant risks and uncertainties that could cause actual results to differ materially.
• Positive Sentiment: The NurOwn technology platform was highlighted for its safety profile and clinical effectiveness in treating neurodegenerative disorders.
• Positive Sentiment: Management reiterated the large market potential for therapies targeting ALS and other neurodegenerative diseases.
• Positive Sentiment: The company stated that its existing capital resources are sufficient to fund operations through 2025 and beyond.
• Neutral Sentiment: BrainStorm plans to pursue strategic collaborations and partnerships to support its clinical development and business objectives.

[Operator]

Greetings, and welcome to the BrainCell BrainStorm Cell Therapeutics second quarter twenty twenty five conference call. At this time, all participants are in a listen only mode. As a reminder, this call is being recorded. And I would now like to introduce your host for today's call, Michael Wood of LifeSci Advisors. Mister Wood, you may begin.

[Speaker 1]

Thank you, Kelly. Good morning, everyone, and thank you for joining us this morning. Before passing it off to company management for prepared remarks, I would like to remind listeners that this conference call will contain numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS, the sufficiency of the company's existing capital resources for continuing operations in 2025 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support its business planning efforts. Forward looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time to time in the company's SEC filings. The company's results may differ materially from those projected on today's call, and the company undertakes no obligation to publicly update any forward looking statements.

[Speaker 1]

Joining us on the call this morning will be Chaim Lebowitz, President and CEO of BrainStorm Doctor Bob Dagger, Executive Vice President and Chief Medical Officer Harrow Hartonian, Executive Vice President and Chief Operating Officer and Ala Patlis, Interim Chief Financial Officer. So I'd now like to turn the call over to Mr. Liebowitz. Please go ahead. Thank you, Mike.

[Speaker 1]

Good morning, everyone. Thank you for joining us today.